Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.33−0.17 (-1.10%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Mineralys Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Mineralys Therapeutics's enterprise value was $1.29B on Nov 11, 2026, against $3.19B a year earlier. Over the last 4 years it ranged from -$1.36M to $3.19B, with a median of $583.34M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.29B | -51.3% |
| 2025 | Dec 31, 2025 | $2.65B | +414.0% |
| 2024 | Dec 31, 2024 | $515.22M | +92.8% |
| 2023 | Dec 29, 2023 | $267.20M | – |
See a number that looks wrong?